SE9904289D0 - Method and camposition for the treatment of adenovairal ocular infections - Google Patents

Method and camposition for the treatment of adenovairal ocular infections

Info

Publication number
SE9904289D0
SE9904289D0 SE9904289A SE9904289A SE9904289D0 SE 9904289 D0 SE9904289 D0 SE 9904289D0 SE 9904289 A SE9904289 A SE 9904289A SE 9904289 A SE9904289 A SE 9904289A SE 9904289 D0 SE9904289 D0 SE 9904289D0
Authority
SE
Sweden
Prior art keywords
camposition
treatment
ocular infections
adenoviral
adenoviral ocular
Prior art date
Application number
SE9904289A
Other languages
English (en)
Swedish (sv)
Inventor
Niklas Arnberg
Goeran Wadell
Original Assignee
Niklas Arnberg
Goeran Wadell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niklas Arnberg, Goeran Wadell filed Critical Niklas Arnberg
Priority to SE9904289A priority Critical patent/SE9904289D0/xx
Publication of SE9904289D0 publication Critical patent/SE9904289D0/xx
Priority to PCT/SE2000/002313 priority patent/WO2001037846A1/en
Priority to HK03104387.0A priority patent/HK1052139B/zh
Priority to AU19086/01A priority patent/AU1908601A/en
Priority to EP00982008A priority patent/EP1231925B1/en
Priority to CNB008161739A priority patent/CN100566722C/zh
Priority to AT00982008T priority patent/ATE297211T1/de
Priority to DE60020729T priority patent/DE60020729T2/de
Priority to JP2000359325A priority patent/JP4559613B2/ja
Priority to US10/997,955 priority patent/US7528113B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
SE9904289A 1999-11-26 1999-11-26 Method and camposition for the treatment of adenovairal ocular infections SE9904289D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9904289A SE9904289D0 (sv) 1999-11-26 1999-11-26 Method and camposition for the treatment of adenovairal ocular infections
PCT/SE2000/002313 WO2001037846A1 (en) 1999-11-26 2000-11-23 Method and composition for the treatment of adenoviral ocular infections
HK03104387.0A HK1052139B (zh) 1999-11-26 2000-11-23 治疗腺病毒眼感染的方法和组合物
AU19086/01A AU1908601A (en) 1999-11-26 2000-11-23 Method and composition for the treatment of adenoviral ocular infections
EP00982008A EP1231925B1 (en) 1999-11-26 2000-11-23 Method and composition for the treatment of adenoviral ocular infections
CNB008161739A CN100566722C (zh) 1999-11-26 2000-11-23 治疗腺病毒眼感染的方法和组合物
AT00982008T ATE297211T1 (de) 1999-11-26 2000-11-23 Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
DE60020729T DE60020729T2 (de) 1999-11-26 2000-11-23 Verfahren und zusammensetzung zur behandlung von adenovirale augeninfektionen
JP2000359325A JP4559613B2 (ja) 1999-11-26 2000-11-27 アデノウイルス眼性感染の治療のための方法および組成物
US10/997,955 US7528113B2 (en) 1999-11-26 2004-11-29 Method and composition for the treatment of adenoviral ocular infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9904289A SE9904289D0 (sv) 1999-11-26 1999-11-26 Method and camposition for the treatment of adenovairal ocular infections

Publications (1)

Publication Number Publication Date
SE9904289D0 true SE9904289D0 (sv) 1999-11-26

Family

ID=20417870

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9904289A SE9904289D0 (sv) 1999-11-26 1999-11-26 Method and camposition for the treatment of adenovairal ocular infections

Country Status (10)

Country Link
US (1) US7528113B2 (enExample)
EP (1) EP1231925B1 (enExample)
JP (1) JP4559613B2 (enExample)
CN (1) CN100566722C (enExample)
AT (1) ATE297211T1 (enExample)
AU (1) AU1908601A (enExample)
DE (1) DE60020729T2 (enExample)
HK (1) HK1052139B (enExample)
SE (1) SE9904289D0 (enExample)
WO (1) WO2001037846A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116140A1 (en) * 2008-05-08 2009-11-11 Nestec S.A. Sialic acid to support the immune system in the elderly
KR101116868B1 (ko) * 2008-10-20 2012-02-29 성균관대학교산학협력단 안질환의 예방 또는 치료용 조성물
US20100119558A1 (en) * 2008-11-10 2010-05-13 Scandivir Ab Ngna compositions and methods of use
WO2011003876A1 (en) 2009-07-07 2011-01-13 Adenovir Pharma Ab New antiviral compounds useful for the treatment or the prevention of epidemic keratoconjonctivitis
CA2921634A1 (en) 2013-08-28 2015-03-05 Adenovir Pharma Ab Multivalent sialic acid derivates
CN104586642A (zh) * 2015-02-06 2015-05-06 武汉中科光谷绿色生物技术有限公司 N-乙酰神经氨酸单体、n-乙酰神经氨酸水合物或n-乙酰神经氨酸盐在个人护理用品中的应用
CN108904633A (zh) * 2018-10-19 2018-11-30 长沙浩然医疗科技有限公司 一种改善视力的眼膏及其制备方法
BR112022019206A2 (pt) * 2020-04-15 2022-11-08 Tx Medic Ab Tratamento de infecções por coronavírus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
SK282950B6 (sk) * 1990-04-24 2003-01-09 Biota Scientific Management Pty Ltd Deriváty alfa-D-neuramínovej kyseliny, spôsob ich prípravy, ich použitie a farmaceutické prípravky na ich báze
ATE116546T1 (de) * 1991-03-07 1995-01-15 Kanto Ishi Pharma Co Ltd Colominsäure und produkte einer teilweisen hydrolyse von colominsäure zur herstellung von arzneimitteln zur behandlung von hepatitis, nephritis und arthritis.
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
GB9312531D0 (en) * 1993-06-17 1993-08-04 Glaxo Group Ltd Process
US5858698A (en) * 1994-04-21 1999-01-12 University Of Alberta Methods for detection of enteropathogenic e. coli
AUPM623994A0 (en) * 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
JP3141693B2 (ja) * 1994-08-16 2001-03-05 ダイキン工業株式会社 シアル酸の９位をフッ素で置換したガングリオシドｇｍ３類縁体及びその中間体
US5962311A (en) * 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
DE19547972A1 (de) * 1995-12-21 1997-07-10 Weropharm Gmbh Heparin zur Prophylaxe und akuten Therapie der allergischen Konjunktivitis
CA2246371A1 (en) 1996-02-14 1997-08-21 The Procter & Gamble Company Urogenital and intestinal disorder compositions comprising a substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor
ES2127110B1 (es) 1996-05-24 1999-12-01 Univ Valladolid Procedimiento para variar las propiedades electricas del moco ocular humano y de sustitutos para uso oftalmico.
EP0823428B1 (en) * 1996-07-22 2002-01-02 Sankyo Company Limited Neuraminic acid derivatives, their preparation and their medical use
SE507028C2 (sv) * 1996-08-06 1998-03-16 Medicarb Ab Ny medicinsk användning
US5719020A (en) * 1996-09-25 1998-02-17 Oklahoma Medical Research Foundation 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens
WO1998048817A1 (en) 1997-05-01 1998-11-05 Cytel Corporation Use of sialyl galactosides and related compounds as anti-angiogenic agents
US20050201952A1 (en) * 1998-01-29 2005-09-15 Yash Sharma Treatment and prevention of viral hepatitis infections
AT408946B (de) 1999-02-18 2002-04-25 Immuno Ag Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation

Also Published As

Publication number Publication date
HK1052139B (zh) 2010-04-23
WO2001037846A1 (en) 2001-05-31
JP4559613B2 (ja) 2010-10-13
JP2001151701A (ja) 2001-06-05
CN100566722C (zh) 2009-12-09
EP1231925B1 (en) 2005-06-08
CN1399552A (zh) 2003-02-26
US7528113B2 (en) 2009-05-05
HK1052139A1 (zh) 2003-09-05
US20050080041A1 (en) 2005-04-14
DE60020729T2 (de) 2006-05-11
DE60020729D1 (de) 2005-07-14
AU1908601A (en) 2001-06-04
ATE297211T1 (de) 2005-06-15
EP1231925A1 (en) 2002-08-21

Similar Documents

Publication Publication Date Title
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
DE60035232D1 (de) (S,S)-Reboxetine zur Behandlung von chronischen Erschöpfungssyndrom
TR200002739T2 (tr) Üst solunum problemlerinin tedavisinde ksilitol kompozisyonları
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
MY119375A (en) Treatment of tinnitus using neuroprotective agents
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
DK1059934T3 (da) Matrixproteinpræparater til sårheling
BR9105783A (pt) Polipeptidio,processo para o tratamento em vidro de neuronios e composicoes celular e farmaceutica
SE9904289D0 (sv) Method and camposition for the treatment of adenovairal ocular infections
TR199801289T2 (en) Terap�tik bile�ikler.
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
ATE554793T1 (de) Konjugat
EP1152760A4 (en) USE OF 4-AMINOPYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES
ATE241640T1 (de) Fusidinsäure-derivate
NO20075831L (no) Krystallinske faste og amorfe former av (-)- halofenat
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
JP2002533400A5 (enExample)
WO2004100899A3 (en) Use of secretin in treatments of disorders associated with the amygdala
AU2396900A (en) Treatment and prevention of hiv and other viral infections
BR0015424A (pt) Análogos de ácido hidroxieicosatetraenóico e, métodos de seu uso em tratamento de distúrbios de olho seco
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon